Physician profile
Jonathan Joseph Lyons
NPI 1588860076
$12,349.84
in general payments reported to CMS, 2019-2025
9 companies · $6,581 in 2025
The $6,581 reported for 2025 was more than what 85% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $5,769 · 2025: $6,581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $928.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,422.00 |
| Food and Beverage | $927.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi US Services INC. | $3,140.00 | 2025 | |
| Genzyme Corporation | $2,578.92 | 2025 | |
| Blueprint Medicines Corporation | $2,480.28 | 2024-2025 | Ayvakit |
| Otsuka Pharmaceutical Co., LTD. | $2,450.00 | 2024 | |
| Biogen, INC. | $800.00 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $375.00 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $239.91 | 2024-2025 | Xifaxan |
| Grifols Shared Services North America, INC. | $157.86 | 2024-2025 | Xembify |
| Astrazeneca Pharmaceuticals LP | $127.87 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.